Eli Lilly’s Foundayo Pill Shows Strong Results in Sleep Apnea Trial, Opening Potential $23 Billion Market
Foundayo cut breathing interruptions by as much as 43.8% in a late-stage sleep apnea trial, supporting a new major market for Lilly.
Foundayo cut breathing interruptions by as much as 43.8% in a late-stage sleep apnea trial, supporting a new major market for Lilly.
Company raises 2026 guidance and launches cost-cutting plan.
CMS resolves hypoglossal nerve stimulation reimbursement confusion by adding 6 new HCPCS codes (effective Jan 1, 2026), viewed as positive for Inspire & Nyxoah.
Inspire Medical shares dropped after Medicare corrected a reimbursement error, prompting Oppenheimer to downgrade the stock while Evercore remained optimistic.
Inspire Medical shares fall after Medicare billing code confusion, but major analysts remain confident in long-term growth.
Morgan Stanley updates ratings for Inspire Medical, DexCom, and Bausch + Lomb, highlighting slowing growth, improving operations, and strong long-term pipelines.